BackMarker Therapeutics Overview

Marker Therapeutics Receivables

Latest receivables for MRKR: $1.4M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$1.38M
43.98% YoYΔ $-1.08M vs prior year quarter

Peer average

Loading

Marker Therapeutics Receivables History

Loading

Marker Therapeutics vs. peers: Receivables Comparison

Loading

Marker Therapeutics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Marker Therapeutics (MRKR) FAQ

As of the most recent data (March 2026), MRKR shows a receivables of $1.4M. That compares with $2.5M in the prior-year period — down 44.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, MRKR's receivables is now $1.4M (was $2.5M) — a 44.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Marker Therapeutics is outperforming or lagging.

Tracking MRKR's receivables over time shows whether Marker Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $1.4M That compares with $2.5M in the prior-year period — down 44.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Marker Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $1.4M) with ownership activity and broader fundamentals.

Marker Therapeutics's receivables is $1.4M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.